Trial Profile
A Multicentre , Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Inadequately Controlled Cancer-Related Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tetrodotoxin (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Therapeutic Use
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00725114).
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00725114).
- 09 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT00725114).